Statin therapy and reductions in low-density lipoprotein cholesterol: Initial clinical data on the potent new statin rosuvastatin
2001 (English)In: American Journal of Cardiology, ISSN 0002-9149, Vol. 87, no 5 SUPPL. 1Article in journal (Refereed) Published
The utility of statins with increased potency in reducing low-density lipoprotein cholesterol (LDL-C) is indicated by evidence that aggressive LDL-C lowering is associated with increased reduction in coronary artery disease risk, and the need for such agents is illustrated by the fact that many patients currently fail to achieve LDL-C target levels during treatment with available drugs. In dose-ranging studies of patients with hypercholesterolemia, the new synthetic statin rosuvastatin (formerly ZD4522) produced significant, dose-dependent reductions in LDL-C compared with placebo across a range of doses. Reductions ranged from 34% at 1 mg per day to 65% at 80 mg per day, with linear regression analysis indicating an additional 4.5% reduction in LDL-C with each doubling of the rosuvastatin dose. Rosuvastatin treatment was well tolerated. Phase 3 clinical trials of this agent are under way.
Place, publisher, year, edition, pages
2001. Vol. 87, no 5 SUPPL. 1
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-27096Local ID: 11743OAI: oai:DiVA.org:liu-27096DiVA: diva2:247647